CVBF included by Financial Times in the list of the 1000 Europe’s Fastest-Growing Companies
We are proud to announce that CVBF has been included in the Financial Times (FT) 1000 report, a list of the companies [...]
CVBF as EMA stakeholder at the Second International Awareness Session for International regulators, academia and non-governamental organisations
On 8-9 March 2018, the European Medicines Agency (EMA) held “the Second International Awareness Session for international regulators, academia and non-governmental organisations”. [...]
Save the date – “EPTRI: a new European Research Infrastructure to foster the translation research in paediatrics”, April 10th, Bari (Italy)
The next meeting of the ID-EPTRI (European Paediatric Translational Research Infrastructure) project, entitled “EPTRI: una nuova Infrastruttura Europea per favorire la Ricerca [...]
DEEP Final meeting: preliminary results
The DEEP (DEferiprone Evaluations in paediatrics) project, a 6-year European Project (FP7) coordinated by CVBF and comprising 23 recruiting centres in European [...]
Orphan medicinal products in Europe: an analysis of marketing authorisation failures and abandoned drugs
On September 2017, the article “Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation [...]
SAVE THE DATE – EMA 2nd International Awareness Session, 8-9 March 2018, London
European Medicines Agency (EMA) is organising its second Awareness Session, in London, on 8-9 March 2018. The full title of the event [...]